AustraliaAustralia's highly regulated, innovation-driven healthcare market offers significant opportunity for life-sciences brands ready to navigate TGA requirements and build trusted local partnerships. Taevas provides end-to-end market entry support so you reach
Select an industry to see regulatory pathways, services, and how Taevas supports your Australia market entry.
Therapeutic Goods Administration (TGA)
Australia's medical devices market is valued at over AUD 12 billion and is governed by the Therapeutic Goods Administration under the Therapeutic Goods Act 1989. Devices must be included in the Australian Register of Therapeutic Goods (ARTG) before they can be supplied, with classification ranging from Class I (lowest risk) to Class III and AIMD (highest risk). Taevas guides international manufacturers through ARTG inclusion, conformity assessment, and local sponsor appointment to ensure compliant and timely market entry.
All medical devices supplied in Australia must be entered on the Australian Register of Therapeutic Goods. Taevas prepares and lodges ARTG inclusion applications tailored to your device classification.
Higher-risk devices (Class IIb, III, and AIMD) require conformity assessment by TGA or a recognised overseas body. Taevas coordinates technical documentation and audit preparation to satisfy TGA conformity requirements.
All overseas manufacturers must appoint an Australian sponsor responsible for regulatory obligations. Taevas can act as or identify a qualified sponsor to fulfil post-market and compliance duties.
TGA mandates ongoing adverse event reporting and periodic safety reviews for all registered devices. Taevas provides continuous vigilance monitoring and incident reporting support to maintain ARTG standing.
Taevas combines deep TGA regulatory expertise with an established network of Australian distributors, KOLs, and healthcare professionals to deliver faster, lower-risk market entry for international life-sciences companies.
Our Australia team has hands-on experience navigating ARTG inclusions, TGA evaluations, and FSANZ applications across medical devices, pharmaceuticals, and complementary medicines. We reduce submission errors and accelerate approval timelines.
We operate across all eight Australian states and territories, with established relationships spanning metropolitan hospital networks, regional health services, pharmacy chains, and specialty retail channels.
Our proven market entry playbook and pre-qualified distributor and sponsor network means clients can move from regulatory submission to first commercial sale significantly faster than going it alone.
Taevas maintains active relationships with vetted Australian distributors across pharmaceutical, medical device, and consumer health channels, enabling rapid partner selection and onboarding for new market entrants.
We connect international brands with leading Australian clinicians, pharmacists, and healthcare professionals who can drive clinical adoption, support product evaluations, and build the peer endorsement essential for market credibility.
From initial regulatory strategy through to post-launch sales performance, Taevas takes full accountability for your Australia market entry, acting as a single partner across registration, logistics, distribution, and commercial growth.
Book a free consultation with our Australia market entry specialists to map your regulatory pathway, identify the right distribution partners, and build a clear timeline to revenue.